TY - JOUR
T1 - The changing clinical spectrum of endocrine adverse events in cancer immunotherapy
AU - Chiloiro, Sabrina
AU - Bianchi, Antonio
AU - Giampietro, Antonella
AU - Milardi, Domenico
AU - De Marinis Grasso, Laura
AU - Pontecorvi, Alfredo
PY - 2021
Y1 - 2021
N2 - Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several malignancies, improving patient survival and quality of life. Endocrinopathies have emerged as a clinically significant group of immune-related adverse events (IRAEs). Although the mechanism of ICI toxicities has not been clarified, inhibition of immune checkpoints reduces immune tolerance to autoantigens, resulting in the development of autoimmunity disorders. We report current evidence regarding endocrine IRAEs that may have diagnostic and therapeutic implications. Management should be focused on a multidisciplinary approach to reach a prompt diagnosis and an appropriate and safe treatment.
AB - Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several malignancies, improving patient survival and quality of life. Endocrinopathies have emerged as a clinically significant group of immune-related adverse events (IRAEs). Although the mechanism of ICI toxicities has not been clarified, inhibition of immune checkpoints reduces immune tolerance to autoantigens, resulting in the development of autoimmunity disorders. We report current evidence regarding endocrine IRAEs that may have diagnostic and therapeutic implications. Management should be focused on a multidisciplinary approach to reach a prompt diagnosis and an appropriate and safe treatment.
KW - adrenal insufficiency
KW - adrenal insufficiency
UR - http://hdl.handle.net/10807/200841
U2 - 10.1016/j.tem.2021.10.009
DO - 10.1016/j.tem.2021.10.009
M3 - Article
SN - 1043-2760
SP - 87
EP - 104
JO - Trends in Endocrinology and Metabolism
JF - Trends in Endocrinology and Metabolism
ER -